Composition, form of production and packaging
Tablets are white or white with a creamy shade of color, round, flat-cylindrical, with a bevel.
1 tab.
adamantyl bromophenylamine 50 mg
- "- 100 mg
Auxiliary substances: potato starch, microcrystalline cellulose, magnesium stearate.
25 pcs. - packings of cellular contour (1) - packs cardboard.
25 pcs. - packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
The drug used for asthenic conditions, positively affects the indicators of physical and mental performance. It is a derivative of adamantane. In the spectrum of the drug, activating, anxiolytic, immunostimulating actions and elements of actoprotective activity are combined. Ladasten does not have hypnose-sedative and muscle relaxant properties, the drug has no addictive potential.
When using Ladasten, in contrast to the action of typical psychostimulants, the phenomena of hyperstimulation, as well as aftereffect in the form of exhaustion of the functional capabilities of the organism, do not develop.
The therapeutic effect of Ladasten in patients with asthenic and anxiety-asthenic disorders manifests itself from the first days of its application in the form of a clear reduction of asthenic symptoms, indicators of emotional stress, somatovegetative manifestations; the drug helps to restore activity and increase endurance.
The mechanism of action of Ladasten is associated with increased release of dopamine from presynaptic terminals, blockade of its reuptake, and enhanced biosynthesis due to the expression of the tyrosine hydroxylase gene, as well as its modulating effect on the GABA-benzodiazepine-chloroform receptor complex, which eliminates the decrease in benzodiazepine receptor developing under stress . LadastenВ® enhances GABA -ergic mediation, reducing the expression of the gene that controls the synthesis of the GABA transporter, which performs a reverse capture of the mediator.
PHARMACOKINETICS
C max is 363.3 ng / ml, T max is 2-4 h.
T 1/2 of the drug - 11.21 p.
INDICATIONS
- asthenic conditions of various genesis, incl. at somatic diseases and after the transferred infectious diseases;
- neurasthenia.
DOSING MODE
Ladasten В® is taken orally, regardless of food intake.
Single dose of the drug - 50-100 mg; The daily dose is 100-200 mg in 2 divided doses.
The drug should not be used after 16 hours. The duration of the course of the drug is 2-4 weeks.
SIDE EFFECT
From the side of the central nervous system: there can be signs of excessive activation and a disorder of falling asleep.
Other: allergic reactions (with increased individual sensitivity to the drug).
CONTRAINDICATIONS
- Pregnancy;
- lactation period;
- children's age till 18 years;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
Contraindicated use of the drug Ladasten В® during pregnancy and lactation (breastfeeding).
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
SPECIAL INSTRUCTIONS
If there are side effects from the CNS, you usually do not need to cancel the drug, it is advisable to reduce its dose.
OVERDOSE
With a significant overdose, it is possible to develop a sedative effect.
Treatment: nonspecific detoxification therapy.
DRUG INTERACTION
Ladasten В® with simultaneous application reduces the hypnotic effect of sodium thiopental.
With simultaneous use with benzodiazepine derivatives, Ladasten В® does not weaken their anxiolytic effect.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 2 years.
